The UW-FHCRC CFAR International Core strives to optimize efficiencies by leveraging diverse global HIV research projects, increasing collaborations and networking, mentoring new US and international investigators, optimizing infrastructure in international settings, and facilitating new research directions. During the past decades. International Core researchers have contributed substantive research to identify effective HIV interventions. In the new 5-year cycle, the International Core is poised to develop a new portfolio of collaborative implementation research that will translate efficacy research to implementation scale-up. The Core will foster synergies between ongoing NIH-supported HIV research projects, promote demonstration projects of interventions and facilitate training and mentorship to determine cost-effectiveness as interventions are implemented.
Our specific aims are:
AIM 1 : To facilitate research to address cutting-edge global HIV issues. We will emphasize implementation science in pilot awards, and promote research on combination HIV prevention, chronic treatment, and vulnerable populations. We will establish a new sub-Core on Economic Evaluation, partnering with the Bill and Melinda Gates Foundation to determine sustainability and cost considerations for implementation.
AIM 2 : To strategically expand and leverage collaborations and research projects. We will extend collaborations from mature partners (Kenya, Peru) to new partners including regional neighbor countries;in addition, we will leverage activities of relevant UW DGH Centers (HAI, l-TECH, Global WACh) and Seattle global health organizations (BMGF, PATH) to facilitate research by CFAR investigators. We will provide infrastructure and co-develop training for international sites with other UW-FHCRC CFAR Cores, including SPRC, Biostatistics and AAlMS. We will support inter-CFAR initiatives: specifically, the Women and HIV and sub-Saharan Africa inter-CFAR collaborations.
AIM 3 : To sustain investment in new investigators and broaden the scope of international partnerships. We will provide support for trainees and join with the Developmental core to support a new Mentored International Investigator Award. We will provide mentoring workshops, and provide accessible mentorship to new international trainees. During the past 5 years, the International Core has realized appreciable return on investment in publications, grants, and new global HIV research leaders. We anticipate expanded relevance and efficiencies directly paralleling needs as the global HIV response transitions from emergent to sustainable strategies.
With 33 million HIV-infected individuals worldwide and continued new HIV infections, it remains critical to optimize HIV prevention and chronic treatment, and to develop mechanisms to translate efficacy research to scaled implementation, incorporating a vision that includes sustainability. The International Core will advance research of direct relevance to global HIV by supporting new investigators, enhancing collaborations, pilot and infrastructure support, and providing innovative training and mentorin
|Stekler, Joanne D; McKernan, Jennifer; Milne, Ross et al. (2015) Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 20:77-80|
|Mohanraj, Rani; Jeyaseelan, Visalakshi; Kumar, Shuba et al. (2015) Cultural adaptation of the Brief COPE for persons living with HIV/AIDS in southern India. AIDS Behav 19:341-51|
|Mackelprang, Romel D; Bigham, Abigail W; Celum, Connie et al. (2014) Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans. J Infect Dis 209:1623-7|
|Gantt, Soren; Cattamanchi, Ashok; Krantz, Elizabeth et al. (2014) Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol 60:127-32|
|Slyker, Jennifer A; Casper, Corey; Tapia, Kenneth et al. (2014) Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy. Clin Infect Dis 58:1333-7|
|Gerdts, Sarah E; Wagenaar, Bradley H; Micek, Mark A et al. (2014) Linkage to HIV care and antiretroviral therapy by HIV testing service type in Central Mozambique: a retrospective cohort study. J Acquir Immune Defic Syndr 66:e37-44|
|Liu, Yi; Rao, Ushnal; McClure, Jan et al. (2014) Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds. PLoS One 9:e94240|
|Puttkammer, Nancy H; Zeliadt, Steven B; Balan, Jean Gabriel et al. (2014) Before and after the earthquake: a case study of attrition from the HIV antiretroviral therapy program in Haiti. Glob Health Action 7:24572|
|Pantalone, David W; Huh, David; Nelson, Kimberly M et al. (2014) Prospective predictors of unprotected anal intercourse among HIV-seropositive men who have sex with men initiating antiretroviral therapy. AIDS Behav 18:78-87|
|Wagner, Thor A; McLaughlin, Sherry; Garg, Kavita et al. (2014) HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345:570-3|
Showing the most recent 10 out of 552 publications